With so many companies trying to solve the coronavirus problem, now's a critical time for the biotech stock.
News & Analysis: Inovio Pharmaceuticals
Companies are testing COVID-19 vaccines right now -- if all goes smoothly, more than one may get to market at “warp speed.”
Shares of the COVID-19 vaccine developer have been on fire in 2020. ,
Is now a good time to get in on this biotech stock?
Investors seem to think a 37% drop this week presents a good opportunity to buy the biotech stock.
And one reason why it isn't.
Lingering disappointment over results announced on Tuesday and an FDA update are weighing on the stock.
The results for INO-4800 were positive, but it’s much too early to celebrate.
The biotech's "positive" results from an early-stage study weren't positive enough for investors.
After an unbelievable week, Investors want to know if these drugmakers have what it takes to keep climbing.